Skip to main content
Back
Watch Compare

Regen BioPharma Inc

Data quality: 100%
Also listed as RGBPP OTC
RGBP
OTC Manufacturing Chemicals
$0.00
▼ $0.00 (-16.67%)
Mkt Cap: 106,159.0
Price
$0.00
Mkt Cap
106,159.0
Day Range
$0.00 — $0.00
52-Week Range
$0.00 — $0.12
Volume
10,000
Open $0.00
50D / 200D Avg
$0.00
73.68% below
50D / 200D Avg
$0.02
97.24% below

Quick Summary

Key Takeaways

Revenue grew 40.22% annually over 5 years — strong growth
Negative free cash flow of -515,153.0
Revenue growth is decelerating — 1Y growth trails 5Y average by 40.22%

Growth

Revenue Growth (5Y)
40.22%
Above sector avg (1.82%)
Revenue (1Y)0.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net Margin-730.03%
Op. Margin-350.35%

Safety

Debt / Equity
N/A
Current Ratio0.03
Interest Coverage-5.20

Valuation

PE (TTM)
-0.06
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.1 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -730.0 -41.5
Rev Growth 5Y % 40.2 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0.00% Revenue Growth (3Y) 36.72%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 40.22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 236,561.0 Net Income (TTM) -1.73 M
ROE N/A ROA -795.99%
Gross Margin N/A Operating Margin -350.35%
Net Margin -730.03% Free Cash Flow (TTM) -515,153.0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.03
Interest Coverage -5.20 Asset Turnover 1.09
Working Capital -6.57 M Tangible Book Value -6.57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.06 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0.45
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -485.27%
Market Cap 106,159.0 Enterprise Value 101,581.0
Per Share
EPS (Diluted TTM) 0.07 Revenue / Share 0.00
FCF / Share 0.00 OCF / Share 0.00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 29.83%
SBC-Adj. FCF N/A Growth Momentum -40.22

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 236,561.0 236,560.0 126,560.0 125,517.0 61,194.0
Net Income -1.27 M -668,255.0 1.16 M 2.44 M -6.77 M
EPS (Diluted) -0.05 -0.16 0.29 — —
Gross Profit — — — — —
Operating Income -338,540.0 -417,221.0 -686,950.0 -339,605.0 -200,771.0
EBITDA — — — — —
R&D Expenses 11,725.0 153,685.0 212,297.0 158,138.0 36,704.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 158,286.0 72,445.0 58,584.0 138,720.0 316,013.0
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 274,628.0 161,084.0 353,617.0 559,002.0 1.21 M
Total Liabilities 6.56 M 5.38 M 5.46 M 8.60 M 14.70 M
Shareholders' Equity -6.28 M -5.22 M -5.10 M -8.04 M -13.49 M
Total Debt — — — — —
Cash & Equivalents 69,555.0 716.0 — 51,204.0 727,162.0
Current Assets 274,628.0 143,351.0 131,037.0 336,422.0 994,124.0
Current Liabilities 6.56 M 5.38 M 5.31 M 8.60 M 14.70 M